CO2021007647A2 - Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos - Google Patents
Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismosInfo
- Publication number
- CO2021007647A2 CO2021007647A2 CONC2021/0007647A CO2021007647A CO2021007647A2 CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2 CO 2021007647 A CO2021007647 A CO 2021007647A CO 2021007647 A2 CO2021007647 A2 CO 2021007647A2
- Authority
- CO
- Colombia
- Prior art keywords
- nanoemulsification
- production methods
- cannabis oil
- oil powder
- powder formulated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL261132A IL261132A (en) | 2018-08-13 | 2018-08-13 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| PCT/IL2019/050268 WO2020035850A1 (en) | 2018-08-13 | 2019-03-11 | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021007647A2 true CO2021007647A2 (es) | 2021-08-30 |
Family
ID=63998426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0007647A CO2021007647A2 (es) | 2018-08-13 | 2021-06-10 | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11712430B2 (enExample) |
| EP (1) | EP3716946A1 (enExample) |
| JP (1) | JP2021535935A (enExample) |
| CN (1) | CN113473965A (enExample) |
| AU (1) | AU2019322212B2 (enExample) |
| BR (1) | BR112021009869A2 (enExample) |
| CO (1) | CO2021007647A2 (enExample) |
| IL (2) | IL261132A (enExample) |
| WO (1) | WO2020035850A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3138630A1 (en) * | 2019-05-02 | 2020-11-05 | Betterlife Pharma Inc. | Cannabinoid stock transdermal formulations |
| US10780075B1 (en) | 2019-07-31 | 2020-09-22 | Etain IP, LLC | Water soluble cannabis composition |
| AU2020330527A1 (en) * | 2019-08-12 | 2022-02-24 | Tenshi Kaizen Private Limited | Cannabidiol orally disintegrating tablets |
| IL295386A (en) * | 2020-07-29 | 2022-10-01 | Karnak Tech Llc | Improved formulations of lipophilic subtances for cosmetic uses |
| EP4057993A2 (en) | 2020-07-29 | 2022-09-21 | Karnak Technologies, LLC | Oral compositions of lipophilic diety supplements, nutraceuticals and beneficial edible oils |
| AU2021317263B2 (en) * | 2020-07-29 | 2024-08-01 | Karnak Technologies, Llc | Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives |
| IL300499A (en) * | 2020-08-14 | 2023-04-01 | Capheads Llc | Dosing capsule made from cannabis-derived resin and methods of making the same |
| CA3114085A1 (en) * | 2021-04-05 | 2022-10-05 | MEC11S Inc. | Composition comprising cannabis extracts and method of manufacturing same |
| JP2023010676A (ja) * | 2021-07-09 | 2023-01-20 | 株式会社東洋新薬 | 固形組成物 |
| CN121752266A (zh) | 2023-06-16 | 2026-03-27 | 湃珂知识产权有限责任公司 | 用于产生具有抗生素特性的大麻素皮米级乳剂的方法和所得的皮米级乳剂 |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
| US12667578B2 (en) | 2024-07-25 | 2026-06-30 | Visionary Assets, Llc | Cryogenic process for making cannabinoid nanoparticles and compositions made thereby |
| WO2026037496A1 (en) * | 2024-08-14 | 2026-02-19 | Tetra Pharm Technologies | A self-emulsifying solid composition comprising a cannabinoid |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011092690A1 (en) | 2010-01-26 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Compositions and methods for prevention and treatment of pulmonary hypertension |
| US8629177B2 (en) * | 2010-08-24 | 2014-01-14 | Aphios Corporation | Nanoencapsulated delta-9-tetrahydrocannabinol |
| ES2739194T3 (es) | 2012-01-19 | 2020-01-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulación y método para aumentar la biodisponibilidad oral de fármacos |
| WO2013172999A1 (en) | 2012-05-16 | 2013-11-21 | Mewa Singh | Pharmaceutical compositions for the delivery of substantially water-insoluble drugs |
| US10213391B2 (en) | 2014-05-06 | 2019-02-26 | Mewa Singh | Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation |
| US20160058866A1 (en) | 2014-09-02 | 2016-03-03 | Ronald D. Sekura | Alternative solutions for the administration of cannabis derived botanical products |
| US9629886B2 (en) | 2015-02-24 | 2017-04-25 | Ers Holdings, Llc | Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil |
| EP3270896A4 (en) | 2015-03-19 | 2018-09-12 | One World Cannabis Ltd. | Preparations of cannabis emulsions and methods thereof |
| DK3302437T4 (da) * | 2015-05-28 | 2026-02-23 | Fresh Cut Dev Llc | Stabile cannabinoidformuleringer |
| BR102015024165A2 (pt) * | 2015-09-18 | 2017-03-28 | Prati Donaduzzi & Cia Ltda | composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso |
| DK3368014T3 (da) * | 2015-10-26 | 2024-01-08 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Nye formuleringer af cannabinoider |
| US20180206518A1 (en) | 2016-04-15 | 2018-07-26 | Ronald Silver | Method of making cannabis oil hydrophilic using emulsifiers and related cannabinoid compositions |
| US20200215022A1 (en) * | 2016-12-20 | 2020-07-09 | Tilray, Inc. | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
| CO2017007962A1 (es) * | 2017-08-04 | 2018-04-19 | Alsec Alimentos Secos S A S | Nanoparticulas oleosas de cannabis microencapsuladas en polvo |
-
2018
- 2018-08-13 IL IL261132A patent/IL261132A/en unknown
-
2019
- 2019-03-11 EP EP19714807.5A patent/EP3716946A1/en not_active Withdrawn
- 2019-03-11 CN CN201980067584.5A patent/CN113473965A/zh active Pending
- 2019-03-11 US US16/958,341 patent/US11712430B2/en active Active
- 2019-03-11 BR BR112021009869A patent/BR112021009869A2/pt not_active IP Right Cessation
- 2019-03-11 JP JP2021547984A patent/JP2021535935A/ja active Pending
- 2019-03-11 WO PCT/IL2019/050268 patent/WO2020035850A1/en not_active Ceased
- 2019-03-11 AU AU2019322212A patent/AU2019322212B2/en active Active
-
2020
- 2020-06-17 IL IL275430A patent/IL275430A/en unknown
-
2021
- 2021-06-10 CO CONC2021/0007647A patent/CO2021007647A2/es unknown
-
2023
- 2023-06-14 US US18/209,954 patent/US20230321031A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021009869A2 (pt) | 2022-05-17 |
| CN113473965A (zh) | 2021-10-01 |
| CA3086887A1 (en) | 2020-02-20 |
| WO2020035850A1 (en) | 2020-02-20 |
| US20210059975A1 (en) | 2021-03-04 |
| US11712430B2 (en) | 2023-08-01 |
| US20230321031A1 (en) | 2023-10-12 |
| EP3716946A1 (en) | 2020-10-07 |
| IL261132A (en) | 2018-11-04 |
| AU2019322212A1 (en) | 2021-04-08 |
| IL275430A (en) | 2020-08-31 |
| AU2019322212B2 (en) | 2022-09-29 |
| JP2021535935A (ja) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021009869A2 (pt) | Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste | |
| CR20210483A (es) | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos | |
| CL2017001893A1 (es) | Uso de prg4 como agente antiinflamatorio | |
| CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| CL2018003432A1 (es) | Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales. | |
| MX2018009824A (es) | Composiciones para el cuidado personal. | |
| PE20200726A1 (es) | Composicion de cannabis | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| MX388693B (es) | Composiciones de nanoparticulas para terapia sostenida. | |
| MX2019000427A (es) | Formas de dosificacion oral de cannabinoide de alta concentracion. | |
| EP4653048A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| SG10201804977UA (en) | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Particle Delivery Components | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
| HRP20201333T1 (hr) | Kompozicija koja sadrži oleosome sa različitom raspodjelom veličina | |
| MX2019009783A (es) | Metodo para fabricar una barra que comprende antitranspirante. | |
| CO2020013182A2 (es) | Método y composición para el tratamiento de trastornos del snc | |
| AR085527A1 (es) | Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
| MX373742B (es) | Composiciones para el cuidado personal que comprenden partículas de superficie modificada y silicona funcionalizada no volátil. | |
| MX393038B (es) | Nanoparticulas para su uso para tratar un trastorno neuronal | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| CO2017007962A1 (es) | Nanoparticulas oleosas de cannabis microencapsuladas en polvo | |
| IT201700067430A1 (it) | Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione | |
| ECSP19018116A (es) | 1arilnaftiridin3carboxamidas 7sustituidas y su uso | |
| MX2020002217A (es) | Tamaño de partícula esférica de sílice para control de rda. |